CX3CL1 and Parkinson disease: In this way, it was demonstrated that the soluble form of CX3CL1 reduces motor alterations, as well as dopaminergic neuronal loss and neuroinflammation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) Parkinson’s disease model [54].